ZS Pharma, a late-stage biotech developing a treatment for hyperkalemia, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The Coppell, TX-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol ZSPH. ZS Pharma initially filed confidentially on April 4, 2014. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
